To evaluate drug performance in EpCAM positive cancer entities, various cell lines comprising breast (BT-474 (Figure 6A), SK-BR-3 (Figure 6B)), prostate (PC-3 (Figure 6C), DU145 (Figure 6D)), Head and Neck (UMSCC-11B (Figure 6E)) and ovarian carcinoma (SKOV-1 (Figure 6F)) were analyzed. The gene discussed is EPCAM; the disease is cancer.